The Second Affiliated Hospital of Nanchang University, No.1, Minde Road, Donghu District, Nanchang, Jiangxi, China; Nursing School of Nanchang University, Nanchang, China.
The Second Affiliated Hospital of Nanchang University, No.1, Minde Road, Donghu District, Nanchang, Jiangxi, China.
J Diabetes Complications. 2022 Nov;36(11):108314. doi: 10.1016/j.jdiacomp.2022.108314. Epub 2022 Sep 28.
With the introduction of flash glucose monitoring (FGM) into the international market in 2014, academics worldwide are exploring whether this device improves glycemic control in participants with diabetes mellitus.
A study was conducted in which participants were evaluated to determine the effect of FGM on glycemic control.
From inception to April 9, 2022, we searched the Cochrane Library, PubMed, SinoMed, Embase, Web of Science, MEDLINE, CNKI, Wan Fang Data, and VIP databases to collect randomized controlled trials (RCTs) related to the effect of FGM on glycemic control in participants with diabetes mellitus. Outcomes included glycated hemoglobin, the occurrence of hypoglycemic events, fasting plasma glucose (FPG), and 2-h postprandial glucose (2hPG) levels. The statistical analysis was performed using R 4.1.3 software.
We included 19 studies involving 2013 participants, all of which were RCTs. Meta-analysis results revealed that compared to self-monitoring of blood glucose (SMBG), FGM significantly reduced glycated hemoglobin levels in participants with type 2 diabetes mellitus [mean difference = -0.74 [95 % CI-1.16, -0.32], P < 0.01] and type 1 diabetes mellitus combined with type 2 diabetes mellitus [mean difference = -1.14 [95 % CI-3.14, 0.87], P < 0.01], with a greater effect in participants aged ≤65 years with type 2 diabetes mellitus (mean difference = -1.38 [95 % CI-2.05, -0.72], P < 0.01). However, there was no effect of FGM on the improvement of glycated hemoglobin levels in patients with type 1 diabetes mellitus [P = 0.45]. Furthermore, fasting plasma glucose levels and 2-h postprandial glucose levels were significantly lower in FGM than SMBG, and the number of hypoglycemic events was also significantly lower.
Comparing SMBG with FGM indicated that FGM improves fasting plasma glucose levels, 2-h postprandial glucose levels, and glycated hemoglobin levels, and it reduces the number of hypoglycemic events.
自 2014 年 flash 血糖监测（FGM）进入国际市场以来，全球学者都在探索该设备是否能改善糖尿病患者的血糖控制水平。
本研究评估了 FGM 对血糖控制的影响。
从创建到 2022 年 4 月 9 日，我们检索了 Cochrane 图书馆、PubMed、中国生物医学文献数据库、Embase、Web of Science、MEDLINE、中国知网、万方数据知识服务平台和维普网，以收集有关 FGM 对糖尿病患者血糖控制影响的随机对照试验（RCT）。结局指标包括糖化血红蛋白、低血糖事件的发生情况、空腹血糖（FPG）和餐后 2 小时血糖（2hPG）水平。统计分析采用 R 4.1.3 软件进行。
我们纳入了 19 项研究，共涉及 2013 名参与者，均为 RCT。Meta 分析结果显示，与自我血糖监测（SMBG）相比，FGM 可显著降低 2 型糖尿病患者的糖化血红蛋白水平[平均差=-0.74，95%CI（-1.16，-0.32），P<0.01]和 1 型糖尿病合并 2 型糖尿病患者的糖化血红蛋白水平[平均差=-1.14，95%CI（-3.14，0.87），P<0.01]，且在≤65 岁的 2 型糖尿病患者中效果更明显[平均差=-1.38，95%CI（-2.05，-0.72），P<0.01]。然而，FGM 对 1 型糖尿病患者糖化血红蛋白水平的改善无影响[P=0.45]。此外，FGM 组的空腹血糖和餐后 2 小时血糖水平明显低于 SMBG 组，低血糖事件的发生次数也明显减少。
与 SMBG 相比，FGM 改善了空腹血糖、餐后 2 小时血糖和糖化血红蛋白水平，减少了低血糖事件的发生。
